[ad_1]
MARSEILLE, France, Sept. 07, 2021 (GLOBE NEWSWIRE) – Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate“or the”Society“), announced today that the Company will hold a conference call on Wednesday, September 15, 2021 at 2:00 p.m. CEST / 8:00 a.m. EDT, to provide an update on business progress in the first half of 2021.
Innate CEO Mondher Mahjoubi, MD, Medical Director Joyson Karakunnel, MD, MSc, FACP and CFO Frédéric Lombard, MBA, will participate in the call.
Virtual event details
The live webcast will be available at the following link:
https://edge.media-server.com/mmc/p/bi2jkpjr
Participants can also reach by phone to ask questions by registering before the event at http://emea.directeventreg.com/registration/3774818. Upon registration, participants will receive call numbers, a direct event access code and a unique registrant ID that they can use 10 minutes before the start of the event to access the event. ‘call. Call reminders will also be sent to registered participants by email the day before the event.
This information is also available in the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company’s website for 90 days after the event.
About Innate Pharma:
Innate Pharma SA is a global clinical-stage oncology-focused biotechnology company dedicated to improving treatments and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.
Innate Pharma’s large antibody portfolio includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.
Innate is a pioneer in understanding Natural Killer cell biology and has extended its expertise in the tumor microenvironment and tumor antigens, as well as in antibody engineering. This innovative approach has resulted in a diverse proprietary portfolio and major alliances with leaders in the biopharmaceutical industry, including Bristol-Myers Squibb, Novo Nordisk A / S, Sanofi, and a multi-product collaboration with AstraZeneca.
Based in Marseille, France, with a US office in Rockville, Maryland, Innate Pharma is listed on Euronext Paris and Nasdaq in the United States.
Learn more about Innate Pharma on www.innate-pharma.com
Information on Innate Pharma shares:
|
ISIN code |
FR0010331421 |
Disclaimer regarding forward-looking information and risk factors:
This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995., is intended to identify forward-looking statements. Although the company believes that its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among others, the uncertainties inherent in research and development, in particular relating to the safety, progress and results of its ongoing and planned clinical and preclinical trials, review and approvals by the regulatory authorities of its product candidates, the Company’s marketing efforts, the Company’s continued ability to raise capital to finance its development, and the overall impact of the COVID-19 epidemic on the global health system as well as the business, financial condition and results of operations of the Company. For further discussion of the risks and uncertainties that could cause the actual results, financial condition, performance or achievements of the Company to differ from those contained in forward-looking statements, please refer to the Risk Factors section ( “Risk factors”) of the Universal Registration Document filed with the Autorité des Marchés Financiers (“AMF”), available on the AMF website http://www.amf-france.org or on the Innate Pharma website, and public filings and statements filed with the US Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31 2020, and subsequent filings and reports filed with the AMF or the SEC, or otherwise made public, by the Company.
This press release and the information it contains do not constitute an offer to sell or a solicitation of an offer to purchase or subscribe for Innate Pharma shares in any country whatsoever.
Source link
